(Q33390747)

26 July 2017

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan (English)

1 reference

multicenter clinical trial

26 July 2017

0 references

1 reference

1 reference

1 reference

T Okusaka

1

1 reference

26 July 2017

K Nakachi

2

1 reference

26 July 2017

A Fukutomi

3

1 reference

26 July 2017

N Mizuno

4

1 reference

26 July 2017

S Ohkawa

5

1 reference

26 July 2017

A Funakoshi

6

1 reference

26 July 2017

M Nagino

7

1 reference

26 July 2017

S Kondo

8

1 reference

26 July 2017

S Nagaoka

9

1 reference

26 July 2017

J Funai

10

1 reference

26 July 2017

M Koshiji

11

1 reference

26 July 2017

Y Nambu

12

1 reference

26 July 2017

J Furuse

13

1 reference

26 July 2017

M Miyazaki

14

1 reference

26 July 2017

Y Nimura

15

1 reference

26 July 2017

language of work or name

English

0 references

publication date

13 July 2010

1 reference

British Journal of Cancer

26 July 2017

1 reference

26 July 2017

103

1 reference

26 July 2017

469-474

1 reference

26 July 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605779

26 July 2017

0 references

cites work

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939781

Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939781

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939781

Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939781

Epidemiology of biliary tract cancers: an update

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939781

Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939781

Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939781

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939781

Gemcitabine in advanced biliary tract cancers

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939781

Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939781

A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939781

Synergistic interaction between cisplatin and gemcitabine in vitro.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939781

Interaction between cisplatin and gemcitabine in vitro and in vivo.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939781

Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome.

28 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605779

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605779

International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from Cancer Incidence in Five Continents Vol. VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605779

Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605779

Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605779

Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997-2002

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20628385

12 December 2020

inferred from PubMed ID database lookup

Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20628385

12 December 2020

inferred from PubMed ID database lookup

Randomized phase II clinical trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20628385

12 December 2020

inferred from PubMed ID database lookup

Gastrosplenic fistula from Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605779

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6605779

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference